蓝铜肽 GHK-Cu

Your body makes this peptide. It's in your blood right now — or at least it was, in much higher concentrations, when you were younger. GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper(II) ions) is a naturally occurring tripeptide that circulates in human serum, saliva, and urine, and it does something unusual: it declines dramatically and measurably with age.^[1] At 20, serum GHK levels average around 200 ng/mL. By 60, that's dropped to roughly 80 ng/mL.^[1] Researchers have spent decades trying to figure out what that decline actually costs us.

What they've found is that GHK-Cu sits at an unusual intersection of biology. It's not just a collagen booster, though it does stimulate collagen synthesis. It's not just an antioxidant, though it activates antioxidant pathways. A 2018 gene expression analysis found that GHK-Cu appears to reset the gene expression patterns of aged or diseased tissue toward healthier states — upregulating over 30 genes involved in tissue repair and downregulating genes associated with cancer progression and inflammation.^[2] That's a striking finding. It's also almost entirely preclinical.

The honest summary: GHK-Cu has some of the most interesting mechanistic data of any peptide in the anti-aging space, and some of the weakest human clinical evidence. If you're considering it, you should understand both halves of that sentence.

Key Takeaways

GHK-Cu is a naturally occurring copper-bound tripeptide that declines from ~200 ng/mL to ~80 ng/mL between ages 20 and 60, which is what drives research interest in supplementing it.

Preclinical evidence shows collagen stimulation, wound healing acceleration, antioxidant pathway activation, and broad gene expression modulation — but human RCT data is essentially absent.

GHK-Cu is not FDA-approved for any indication. Injectable forms have no legal commercial pathway in the US; topical cosmetic use exists in a separate regulatory category.

Human safety data on injectable GHK-Cu is limited. Copper toxicity is a theoretical concern at high doses, though it hasn't been documented in published studies.

The compound is available through research chemical vendors and some compounding channels, but without clinical trial validation of dose, safety, or efficacy in humans.

Class	Copper-binding tripeptide
Amino Acid Sequence	Glycyl-L-histidyl-L-lysine (Gly-His-Lys)
Amino Acid Count	3
Mechanism	Copper-mediated regulation of collagen synthesis, gene expression, and antioxidant pathways
FDA Status	Research only — not approved for any indication
Administration	Topical (cosmetic use); subcutaneous injection (research/off-label)
Typical Dose	No established clinical dose; practitioner-reported, not confirmed in published clinical trials
Half-life	Not established in published human studies; practitioner-reported, not confirmed in published clinical trials
Primary Uses	Skin repair, wound healing, anti-aging research, extracellular matrix modulation
Evidence Level	Preclinical / in vitro / animal models; limited human data

---

There are no published randomized clinical trials establishing an official dose for GHK-Cu. The ranges below reflect what practitioners and researchers commonly report, based on available protocol guides and community consensus — not validated clinical trial data.

No clinical dosing data exists for injectable GHK-Cu

The dose ranges discussed here are not derived from randomized clinical trials. They represent practitioner and community consensus only. No regulatory body has validated a safe or effective dose for injectable GHK-Cu in humans. Dosing should be discussed with a licensed healthcare provider familiar with this compound.

For topical application, GHK-Cu is the most studied route. Cosmetic formulations typically contain GHK-Cu at concentrations ranging from 0.5% to 5% by weight — though GHK-Cu concentration in formulations is not established in human clinical data; concentrations used in research models and cosmetic applications vary and are not standardized — and this is the only route with any meaningful human use data — though even here, most studies are industry-funded and lack rigorous controls.^[3]

For subcutaneous injection, some practitioners have reported doses in the range of 1–3 mg per injection, administered once daily or several times per week, though GHK-Cu dosing in humans has not been established in clinical trials and these figures lack peer-reviewed verification. Any higher doses described for acute wound healing contexts carry the same caveat — practitioner-reported, no clinical trial data available. None of these ranges have been validated in published human trials. Injection site rotation is standard practice with any subcutaneous peptide protocol.

If published dosing guidance for injectable GHK-Cu matters to you — and it should — the honest answer is that it doesn't exist yet. A licensed provider who works with this compound regularly is your best source for current practitioner consensus.

---

Most peptides do one thing well. GHK-Cu appears to do several things through a single mechanism — and that's what makes the research genuinely interesting, even if the clinical evidence hasn't caught up yet.

The copper ion isn't decorative. Copper is a redox-active metal, meaning it can shuttle between oxidation states (Cu+ and Cu2+), and that chemistry is central to how GHK-Cu interacts with tissue. The peptide acts as a copper transport and delivery system, shuttling copper ions to enzymes and cellular processes that depend on them — including lysyl oxidase, which crosslinks collagen and elastin fibers to give them structural integrity.^[4]

The gene expression finding worth knowing about

A 2018 analysis of GHK-Cu's effects on gene expression found it modulated over 50 genes involved in tissue remodeling, antioxidant defense, and anti-inflammatory signaling — and appeared to shift the expression profile of aged tissue toward patterns more typical of younger, healthier cells. This was based on database analysis and in vitro work, not a human trial. But the breadth of the effect is what distinguishes GHK-Cu from simpler collagen-stimulating compounds.^[2]

Compare that to something like a retinoid or a simple growth factor: those work through narrower pathways. GHK-Cu's apparent ability to influence gene expression at scale — if it holds up in human trials — would put it in a different category entirely. That's the "if" doing a lot of work in that sentence.

---

Start with the copper. Copper(II) ions bound to the Gly-His-Lys tripeptide form a stable chelate — a molecular structure where the peptide wraps around the copper ion, holding it in a biologically active form that cells can use.^[5] This matters because free copper ions are toxic at high concentrations. The peptide keeps copper bioavailable without letting it run loose.

Once in tissue, GHK-Cu operates through several overlapping mechanisms:

Extracellular matrix remodeling. GHK-Cu stimulates dermal fibroblasts — the cells responsible for producing collagen, elastin, and glycosaminoglycans (the structural proteins and sugars that give skin and connective tissue its architecture). Crucially, it doesn't just stimulate synthesis; it also regulates breakdown. It modulates matrix metalloproteinases (MMPs, enzymes that degrade old collagen) and their inhibitors (TIMPs), which means it helps balance the turnover cycle rather than simply dumping more collagen into tissue.^[4] That balance is what distinguishes healthy remodeling from fibrosis.

Gene expression modulation. This is the most striking part of the mechanism. GHK-Cu appears to interact with the cell nucleus in ways that alter transcription patterns — which genes get turned on or off. The 2018 analysis identified effects on genes related to inflammation suppression, antioxidant defense (including superoxide dismutase and catalase pathways), and even tumor suppressor activity.^[2] The mechanism behind this nuclear interaction isn't fully characterized yet.

Antioxidant pathway activation. GHK-Cu upregulates enzymatic antioxidant defenses rather than acting as a direct antioxidant itself. This is a more durable strategy than simply scavenging free radicals — it trains the cell to produce its own defenses.^[2]

Angiogenesis and nerve outgrowth. Animal and in vitro studies show GHK-Cu promotes new blood vessel formation and nerve fiber growth, which accelerates wound healing by improving tissue perfusion and innervation.^[4] Whether this translates meaningfully to human clinical outcomes at achievable doses remains unconfirmed.

---

Be clear about what "clinical evidence" means here: for GHK-Cu, most of it is in vitro (cells in a dish) or animal models. Human trial data is thin.

In vitro and cell studies consistently show GHK-Cu stimulates collagen and glycosaminoglycan synthesis in human dermal fibroblasts.^[4] It restores replicative vitality to fibroblasts that have been damaged by radiation — a finding with potential implications for post-radiation wound healing.^[4] These are real effects in real human cells. They just haven't been confirmed in controlled human trials.

Animal studies show accelerated wound healing, reduced inflammation, and improved tissue repair in skin, lung connective tissue, bone, liver, and stomach lining.^[2] The breadth of tissue types is notable. So is the fact that animal pharmacokinetics don't always translate to humans.

Topical human data exists, but it's largely from cosmetic industry studies — small, often uncontrolled, and not published in peer-reviewed journals with independent oversight.^[3] A 2025 review of topically applied GHK as an anti-wrinkle peptide noted the compound's genuine mechanistic promise while acknowledging that rigorous, large-scale human trials are lacking.^[3] Topical bioavailability is also genuinely uncertain — skin is designed to keep things out, and whether GHK-Cu penetrates deeply enough to reach fibroblasts at cosmetically relevant concentrations is debated.^[3]

The aging decline data is real and reproducible: serum GHK drops from ~200 ng/mL at age 20 to ~80 ng/mL by age 60.^[1] What's not established is whether supplementing GHK-Cu reverses the biological consequences of that decline, or whether the decline is a cause of aging versus a marker of it.

---

• Human RCT efficacy data — No randomized, placebo-controlled trial has demonstrated that injectable or topical GHK-Cu produces measurable clinical outcomes in humans at specific doses. The in vitro and animal data is compelling; the human trial data doesn't exist yet.
• Injectable bioavailability and pharmacokinetics — We don't have published human data on how subcutaneous GHK-Cu is absorbed, distributed, or eliminated. Half-life in humans is not established.
• Dose-response relationship — No published study has characterized what dose produces what effect in humans. The practitioner ranges in use today are extrapolated from animal studies and clinical intuition, not controlled trials.
• Long-term safety — Copper accumulation with repeated dosing is a theoretical concern. No long-term human safety studies exist for injectable GHK-Cu.
• Topical penetration depth — Whether topically applied GHK-Cu reaches dermal fibroblasts at concentrations sufficient to produce the effects seen in cell culture remains unresolved.^[3]
• Causality vs. correlation in aging decline — The drop in serum GHK with age is documented, but whether restoring those levels reverses aging-related tissue changes in humans is unproven.

---

Human clinical safety data for injectable GHK-Cu is essentially absent from the published literature. What follows is based on theoretical pharmacology, animal data, and practitioner-reported experience — not clinical trial adverse event tables.

Topical use:

• Skin irritation — Reported occasionally with higher-concentration formulations, typically mild redness or sensitivity. Generally resolves with reduced concentration or frequency.
• Discoloration — Copper-containing compounds may theoretically cause temporary discoloration at application sites; however, no clinical data on GHK-Cu application-site effects in humans are available.

Injectable use (based on practitioner reports, not clinical trials):

• Injection site reactions — Redness, mild swelling, or tenderness at the injection site. Standard with any subcutaneous peptide; rotation of sites reduces recurrence.
• Copper-related effects — At high doses, copper toxicity can cause nausea, headache, and in severe cases, liver and kidney effects. Whether this is achievable at typical GHK-Cu research doses is unknown, but it's the right thing to watch for.
• Metallic taste — Reported anecdotally by some users shortly after injection, though metallic taste has not been documented in available clinical or preclinical literature for GHK-Cu.

If you're using injectable GHK-Cu and notice unusual fatigue, nausea, or abdominal pain, those are worth flagging with a provider who knows your protocol. Copper toxicity is rare but real, and it's the one risk specific to this compound that distinguishes it from peptides without a metal ion component.

---

Access status — US, as of 2026-03

GHK-Cu is not FDA-approved for any therapeutic indication. Injectable GHK-Cu has no legal commercial pathway in the United States — it cannot be prescribed through standard channels or dispensed by licensed compounding pharmacies as a finished therapeutic product. It is classified as research-only. Topical cosmetic products containing GHK-Cu are sold legally under cosmetic (not drug) regulations, which means they are not subject to FDA efficacy review.

The regulatory picture here has two distinct layers. Topical GHK-Cu in cosmetic formulations is legal and widely sold — you'll find it in serums, creams, and eye treatments from dozens of brands. The FDA regulates these as cosmetics, not drugs, which means the manufacturer doesn't need to prove efficacy, only that the product isn't harmful. Buyer beware applies here: cosmetic labeling claims are not the same as clinical evidence.

Injectable GHK-Cu is a different story. There's no FDA-approved injectable form, no NDA, and no IND (Investigational New Drug) application for human use that's publicly available^[6]. It circulates in the research chemical market and is used by some practitioners off-label, but that use exists outside any regulatory framework that provides patient protection.

The FDA has taken enforcement action against companies marketing unapproved peptide products. Patients and providers should consult FDA.gov and the FDA's MedWatch program for current enforcement activity.

---

Injectable GHK-Cu is available through research chemical vendors. If you're going to use it — and many people will regardless of the regulatory status — here's what actually matters for safety:

What to look for:

• Third-party Certificate of Analysis (COA) — The lab testing the product should be independent of the vendor. An in-house COA from the vendor's own lab means nothing. Look for testing from established analytical labs with verifiable contact information.
• HPLC purity report — High-performance liquid chromatography purity should be 98% or higher for research-grade peptides. Lower than that and you're getting meaningful amounts of something other than what you ordered.
• Copper content verification — Because GHK-Cu contains a metal ion, mass spectrometry or ICP-MS (inductively coupled plasma mass spectrometry) verification of the copper:peptide ratio is worth asking for. Not all vendors provide this.
• Sterility testing — For anything injectable, sterility and endotoxin testing matters. Bacterial endotoxins cause fever and inflammatory reactions. This is non-negotiable.

Red flags:

• No COA or "available on request" without follow-through — If a vendor can't produce a current COA within 24 hours, move on.
• Price significantly below market — Peptide synthesis and proper testing cost real money. Pricing that seems too good typically reflects corners being cut somewhere in that process.
• Claims of FDA approval or "pharmaceutical grade" — Neither applies to research chemical GHK-Cu. Any vendor making these claims is either confused or lying.
• No clear reconstitution guidance — Legitimate research peptide vendors provide technical documentation. Vendors who don't know how their product should be handled are a warning sign.

---

If tissue repair and anti-aging are what you're researching, a few related compounds are worth understanding in context. BPC-157 has a broader tissue repair evidence base in animal models and is more commonly used in injectable protocols by practitioners. Thymosin Beta-4 (TB-500) targets actin polymerization and has shown wound healing effects in animal studies with some human data from ophthalmology trials. For collagen-focused outcomes specifically, GHK-Cu's mechanism is more directly relevant than either of those — but its human evidence gap is also wider.

Tissue Repair Peptides: How They Compare

Parameter	GHK-Cu	BPC-157	TB-500
Primary mechanism	Copper-mediated collagen remodeling + gene expression	Nitric oxide + growth factor pathways	Actin polymerization / cell migration
Best evidence base	In vitro / animal	Animal models	Animal + limited human (ophthalmology)
FDA status	Research only	Research only	Research only
Injectable human trials	None published	None published	Limited
Topical use	Yes (cosmetic)	No	No

---